Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex
about
Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile diseaseVaccinations for Neuroinfectious Disease: A Global Health PriorityComputational prediction of Usutu virus E protein B-cell and T-cell epitopes for potential vaccine developmentA review of West Nile and Usutu virus co-circulation in Europe: how much do transmission cycles overlap?Current epidemiology and clinical practice in arboviral infections - implications on blood supply in South-East Asia.Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus.Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.A High-Performance Multiplex Immunoassay for Serodiagnosis of Flavivirus-Associated Neurological Diseases in Horses.JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibodyAn inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibodyInternal ribosome entry site-based attenuation of a flavivirus candidate vaccine and evaluation of the effect of beta interferon coexpression on vaccine propertiesVaccines and vaccination against tick-borne encephalitis.Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.Fatal transplant-associated west nile virus encephalitis and public health investigation-california, 2010.Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.Zika virus infection confers protection against West Nile virus challenge in mice.Tick-borne encephalitis in Japan, Republic of Korea and China.Preconceptual Zika virus asymptomatic infection protects against secondary prenatal infection.Latency, persistence and reactivation of Japanese encephalitis virus
P2860
Q24273313-BD0F9863-AAF8-44DB-9B3B-F38C03516595Q26252588-3E8FF655-340B-4042-8FA3-FED242A90BCCQ28954647-E9168B53-07C8-480F-BA4C-1EC3807D9638Q34044677-3DA12350-6EA6-4965-B9AE-582C9A3ECE9EQ34079344-172481D4-C644-4253-895C-1A62D930C60EQ34208783-EC7F0FA0-C193-41FB-A3F9-80A8854F9CD3Q35818688-C0999366-ACE7-46B3-A0D4-A65B1917C56BQ36109311-6263CBC5-7AE6-4180-A21E-E3D671D4DCA2Q36760059-314D79BE-0F82-4BCB-8A2B-F4409EBEE3DBQ37123147-8F1C2E27-02CA-441B-AED9-21778E45E2D2Q37547088-175409BA-6A0A-4823-AB83-04DF39E6D498Q38059753-9925C761-B471-497A-9E49-6C0C9732C2FEQ39039111-344AC371-DC79-488F-B153-2BCF51556B44Q40242280-717ECF57-FD1B-4762-97E0-A29E29062CAEQ41146226-E6887E85-C4AD-4DBF-B613-A6E1470C9862Q41918368-B3EB939B-F48D-4314-A2E4-7A84066B6843Q41934268-F6587F0D-222A-4C25-B245-6DB562F3D1B7Q45324741-1F9750BA-D3E7-453A-A7CF-F41030D8694FQ56749405-AA1E65D4-6303-482D-AC6F-850CACA6D399
P2860
Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@ast
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@en
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@nl
type
label
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@ast
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@en
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@nl
prefLabel
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@ast
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@en
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@nl
P2860
P921
P356
P1476
Feasibility of cross-protectiv ...... anese encephalitis serocomplex
@en
P2093
Mario Lobigs
P2860
P304
P356
10.1586/ERV.11.180
P407
P577
2012-02-01T00:00:00Z